← Evidence map

ReviewCureus2026

Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review.

Amir Meftah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review. | Socratic